{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:28:13Z","timestamp":1790368093996,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The concept of progressive fibrosing interstitial lung disease (PF-ILD) has recently emerged. However, real-life proportion of PF-ILDs outside IPF is still hard to evaluate. Therefore, we sought to estimate the proportion of PF-ILD in our ILD cohort. We also determined the proportion of ILD subtypes within PF-ILD and investigated factors associated with PF-ILDs. Finally, we quantified interobserver agreement between radiologists for the assessment of fibrosis. We reviewed the files of ILD patients discussed in multidisciplinary discussion between January 1st 2017 and December 31st 2019. Clinical data, pulmonary function tests (PFTs) and high-resolution computed tomography (HRCTs) were centrally reviewed. Fibrosis was defined as the presence of traction bronchiectasis, reticulations with\/out honeycombing. Progression was defined as a relative forced vital capacity (FVC) decline of\u2009\u2265\u200910% in\u2009\u2264\u200924\u00a0months or 5%\u2009&lt;\u2009FVC decline\u2009&lt;\u200910% and progression of fibrosis on HRCT in\u2009\u2264\u200924\u00a0months. 464 consecutive ILD patients were included. 105 had a diagnosis of IPF (23%). Most frequent non-IPF ILD were connective tissue disease (CTD)-associated ILD (22%), hypersensitivity pneumonitis (13%), unclassifiable ILD (10%) and sarcoidosis (8%). Features of fibrosis were common (82% of CTD-ILD, 81% of HP, 95% of uILD). After review of HRCTs and PFTs, 68 patients (19% of non-IPF ILD) had a PF-ILD according to our criteria. Interobserver agreement for fibrosis between radiologists was excellent (Cohen\u2019s kappa 0.86). The main diagnosis among PF-ILD were CTD-ILD (36%), HP (22%) and uILD (20%). PF-ILD patients were significantly older than non-F-ILD (P\u2009=\u20090.0005). PF-ILDs represent about 20% of ILDs outside IPF. This provides an estimation of the proportion of patients who might benefit from antifibrotics. Interobserver agreement between radiologists for the diagnosis of fibrotic ILD is excellent.<\/jats:p>","DOI":"10.1038\/s41598-021-03481-8","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T06:03:55Z","timestamp":1639461835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Real-life prevalence of progressive fibrosing interstitial lung diseases"],"prefix":"10.1038","volume":"11","author":[{"given":"Maureen","family":"Gagliardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damienne Vande","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles-Edouard","family":"Heylen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Hoton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Tamirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Ghaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Froidure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"3481_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis, W. D. et al. An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188, 733\u2013748. https:\/\/doi.org\/10.1164\/rccm.201308-1483ST (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3481_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1164\/ajrccm.162.2.9909015","volume":"162","author":"R Lazor","year":"2000","unstructured":"Lazor, R. et al. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d\u2019Etudes et de Recherche sur les Maladles \u201cOrphelines\u201d Pulmonaires (GERM\"O\"P). Am. J. Respir. Crit. Care Med. 162, 571\u2013577. https:\/\/doi.org\/10.1164\/ajrccm.162.2.9909015 (2000).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3481_CR3","doi-asserted-by":"publisher","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research, N. et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366, 1968\u20131977, doi:https:\/\/doi.org\/10.1056\/NEJMoa1113354 (2012).","DOI":"10.1056\/NEJMoa1113354"},{"key":"3481_CR4","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King, T. E. Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1402582 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3481_CR5","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2071\u20132082. https:\/\/doi.org\/10.1056\/NEJMoa1402584 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3481_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02279-2019","author":"J Behr","year":"2020","unstructured":"Behr, J. et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.02279-2019 (2020).","journal-title":"Eur. Respir. J."},{"key":"3481_CR7","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/thoraxjnl-2016-209172","volume":"71","author":"SK Mathai","year":"2016","unstructured":"Mathai, S. K., Newton, C. A., Schwartz, D. A. & Garcia, C. K. Pulmonary fibrosis in the era of stratified medicine. Thorax 71, 1154\u20131160. https:\/\/doi.org\/10.1136\/thoraxjnl-2016-209172 (2016).","journal-title":"Thorax"},{"key":"3481_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12931-017-0692-9","volume":"18","author":"KD Samara","year":"2017","unstructured":"Samara, K. D. et al. Upregulation of citrullination pathway: From autoimmune to idiopathic lung fibrosis. Respir. Res. 18, 218. https:\/\/doi.org\/10.1186\/s12931-017-0692-9 (2017).","journal-title":"Respir. Res."},{"key":"3481_CR9","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","volume":"379","author":"PA Juge","year":"2018","unstructured":"Juge, P. A. et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N. Engl. J. Med. 379, 2209\u20132219. https:\/\/doi.org\/10.1056\/NEJMoa1801562 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3481_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00692-2018","author":"AU Wells","year":"2018","unstructured":"Wells, A. U. et al. What\u2019s in a name? That which we call IPF, by any other name would act the same. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.00692-2018 (2018).","journal-title":"Eur. Respir. J."},{"key":"3481_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/resp.13442","volume":"24","author":"CJ Ryerson","year":"2019","unstructured":"Ryerson, C. J. Lumpers versus splitters: What to do with suspected idiopathic pulmonary fibrosis?. Respirology 24, 300\u2013301. https:\/\/doi.org\/10.1111\/resp.13442 (2019).","journal-title":"Respirology"},{"key":"3481_CR12","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3481_CR13","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty, K. R. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 381, 1718\u20131727. https:\/\/doi.org\/10.1056\/NEJMoa1908681 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3481_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30341-8","author":"TM Maher","year":"2019","unstructured":"Maher, T. M. et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir. Med. https:\/\/doi.org\/10.1016\/S2213-2600(19)30341-8 (2019).","journal-title":"Lancet Respir. Med."},{"key":"3481_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr, J. et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir. Med 9, 476\u2013486. https:\/\/doi.org\/10.1016\/S2213-2600(20)30554-3 (2021).","journal-title":"Lancet Respir. Med"},{"key":"3481_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12931-021-01749-1","volume":"22","author":"M Nasser","year":"2021","unstructured":"Nasser, M. et al. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). Respir. Res. 22, 162. https:\/\/doi.org\/10.1186\/s12931-021-01749-1 (2021).","journal-title":"Respir. Res."},{"key":"3481_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02718-2020","author":"M Nasser","year":"2021","unstructured":"Nasser, M. et al. Progressive fibrosing interstitial lung disease: A clinical cohort (the PROGRESS study). Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.02718-2020 (2021).","journal-title":"Eur. Respir. J."},{"key":"3481_CR18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00221-2021","author":"T Simpson","year":"2021","unstructured":"Simpson, T. et al. The burden of progressive fibrotic interstitial lung disease across the UK. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.00221-2021 (2021).","journal-title":"Eur. Respir. J."},{"key":"3481_CR19","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek, M. et al. Progressive fibrosing interstitial lung diseases: Current practice in diagnosis and management. Curr. Med. Res. Opin. 35, 2015\u20132024. https:\/\/doi.org\/10.1080\/03007995.2019.1647040 (2019).","journal-title":"Curr. Med. Res. Opin."},{"key":"3481_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106626","volume":"189","author":"T Goos","year":"2021","unstructured":"Goos, T. et al. Defining and predicting progression in non-IPF interstitial lung disease. Respir. Med. 189, 106626. https:\/\/doi.org\/10.1016\/j.rmed.2021.106626 (2021).","journal-title":"Respir. Med."},{"key":"3481_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.36141\/svdld.v36i2.8107","volume":"36","author":"C Biglia","year":"2019","unstructured":"Biglia, C. et al. Multidisciplinary management of interstitial lung diseases: A real-life study. Sarcoidosis Vasc Diffuse Lung Dis. 36, 108\u2013115. https:\/\/doi.org\/10.36141\/svdld.v36i2.8107 (2019).","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"3481_CR22","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0051-2017","author":"H Robbie","year":"2017","unstructured":"Robbie, H., Daccord, C., Chua, F. & Devaraj, A. Evaluating disease severity in idiopathic pulmonary fibrosis. Eur. Respir. Rev. https:\/\/doi.org\/10.1183\/16000617.0051-2017 (2017).","journal-title":"Eur. Respir. Rev."},{"key":"3481_CR23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02718-2020","author":"M Nasser","year":"2020","unstructured":"Nasser, M. et al. Progressive fibrosing interstitial lung disease: A clinical cohort (the PROGRESS(R) study). Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.02718-2020 (2020).","journal-title":"Eur. Respir. J."},{"key":"3481_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163894","volume":"11","author":"VK Jaeger","year":"2016","unstructured":"Jaeger, V. K. et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study. PLoS ONE 11, e0163894. https:\/\/doi.org\/10.1371\/journal.pone.0163894 (2016).","journal-title":"PLoS ONE"},{"key":"3481_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells, A. U. et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir. Med. 8, 453\u2013460. https:\/\/doi.org\/10.1016\/S2213-2600(20)30036-9 (2020).","journal-title":"Lancet Respir. Med."},{"key":"3481_CR26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01983-2019","author":"LJ De Sadeleer","year":"2020","unstructured":"De Sadeleer, L. J. et al. Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.01983-2019 (2020).","journal-title":"Eur. Respir. J."},{"key":"3481_CR27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00398-2016","author":"M Selman","year":"2016","unstructured":"Selman, M., Lopez-Otin, C. & Pardo, A. Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.00398-2016 (2016).","journal-title":"Eur. Respir. J."},{"key":"3481_CR28","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1073\/pnas.1504780112","volume":"112","author":"JK Alder","year":"2021","unstructured":"Alder, J. K. et al. Telomere dysfunction causes alveolar stem cell failure. Proc. Natl. Acad. Sci. U.S.A. 112, 5099\u20135104. https:\/\/doi.org\/10.1073\/pnas.1504780112 (2021).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"3481_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1534\/genetics.113.152322","volume":"194","author":"Z Xu","year":"2013","unstructured":"Xu, Z., Duc, K. D., Holcman, D. & Teixeira, M. T. The length of the shortest telomere as the major determinant of the onset of replicative senescence. Genetics 194, 847\u2013857. https:\/\/doi.org\/10.1534\/genetics.113.152322 (2013).","journal-title":"Genetics"},{"key":"3481_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41590-017-0030-x","volume":"19","author":"JH Kim","year":"2018","unstructured":"Kim, J. H. et al. Aged polymorphonuclear leukocytes cause fibrotic interstitial lung disease in the absence of regulation by B cells. Nat. Immunol. 19, 192\u2013201. https:\/\/doi.org\/10.1038\/s41590-017-0030-x (2018).","journal-title":"Nat. Immunol."},{"key":"3481_CR31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-019-1658-5","volume":"574","author":"S Mahmoudi","year":"2019","unstructured":"Mahmoudi, S. et al. Heterogeneity in old fibroblasts is linked to variability in reprogramming and wound healing. Nature 574, 553\u2013558. https:\/\/doi.org\/10.1038\/s41586-019-1658-5 (2019).","journal-title":"Nature"},{"key":"3481_CR32","doi-asserted-by":"publisher","first-page":"L721","DOI":"10.1152\/ajplung.00410.2011","volume":"302","author":"H Tanjore","year":"2012","unstructured":"Tanjore, H., Blackwell, T. S. & Lawson, W. E. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 302, L721-729. https:\/\/doi.org\/10.1152\/ajplung.00410.2011 (2012).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"3481_CR33","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1183\/13993003.00308-2016","volume":"48","author":"CA Newton","year":"2016","unstructured":"Newton, C. A. et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur. Respir. J. 48, 1710\u20131720. https:\/\/doi.org\/10.1183\/13993003.00308-2016 (2016).","journal-title":"Eur. Respir. J."},{"key":"3481_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/thoraxjnl-2015-207252","volume":"71","author":"SL Walsh","year":"2016","unstructured":"Walsh, S. L. et al. Interobserver agreement for the ATS\/ERS\/JRS\/ALAT criteria for a UIP pattern on CT. Thorax 71, 45\u201351. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207252 (2016).","journal-title":"Thorax"},{"key":"3481_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12916-015-0479-0","volume":"13","author":"SL Walsh","year":"2015","unstructured":"Walsh, S. L. et al. Relationship between fibroblastic foci profusion and high resolution CT morphology in fibrotic lung disease. BMC Med. 13, 241. https:\/\/doi.org\/10.1186\/s12916-015-0479-0 (2015).","journal-title":"BMC Med."},{"key":"3481_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s41669-019-00191-w","volume":"4","author":"C Rinciog","year":"2020","unstructured":"Rinciog, C. et al. Cost-effectiveness analysis of nintedanib versus pirfenidone in idiopathic pulmonary fibrosis in Belgium. Pharmacoecon. Open 4, 449\u2013458. https:\/\/doi.org\/10.1007\/s41669-019-00191-w (2020).","journal-title":"Pharmacoecon. Open"},{"key":"3481_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/2050-6511-15-63","volume":"15","author":"E Loveman","year":"2014","unstructured":"Loveman, E. et al. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: Systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol. Toxicol. 15, 63. https:\/\/doi.org\/10.1186\/2050-6511-15-63 (2014).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"3481_CR38","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1080\/03007995.2018.1433143","volume":"34","author":"F Porte","year":"2018","unstructured":"Porte, F. et al. Health economic evaluation in idiopathic pulmonary fibrosis in France. Curr. Med. Res. Opin. 34, 1731\u20131740. https:\/\/doi.org\/10.1080\/03007995.2018.1433143 (2018).","journal-title":"Curr. Med. Res. Opin."},{"key":"3481_CR39","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George, P. M. et al. Progressive fibrosing interstitial lung disease: Clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir. Med. 8, 925\u2013934. https:\/\/doi.org\/10.1016\/S2213-2600(20)30355-6 (2020).","journal-title":"Lancet Respir. Med."},{"key":"3481_CR40","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S2213-2600(21)00017-5","volume":"9","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo, P. et al. Early diagnosis of fibrotic interstitial lung disease: Challenges and opportunities. Lancet Respir. Med. 9, 1065\u20131076. https:\/\/doi.org\/10.1016\/S2213-2600(21)00017-5 (2021).","journal-title":"Lancet Respir. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03481-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03481-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03481-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:01:18Z","timestamp":1670072478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03481-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3481"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03481-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"27 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Froidure reports grants and personal fees from Boehringer Ingelheim, grants from Roche, personal fees from Chiesi, outside the submitted work. The other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23988"}}